Page last updated: 2024-11-08

menthofuran

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

menthofuran: RN given refers to cpd without isomeric designation; derives from cyclization of pulegone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

menthofuran : A monoterpenoid that is 4,5,6,7-tetrahydro-1-benzofuran substituted by methyl groups at positions 3 and 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID329983
CHEMBL ID1522900
CHEBI ID50542
SCHEMBL ID1472618
MeSH IDM0153831

Synonyms (50)

Synonym
3,6-dimethyl-4,5,6,7-tetrahydro-benzofuran
p-mentha-3,8-diene, 3,9-epoxy-
benzofuran, 4,5,6,7-tetrahydro-3,6-dimethyl-
p-mentha-3, 3,9-epoxy-
menthofurane
nsc-315249
benzofuran,5,6,7-tetrahydro-3,6-dimethyl-
3,8-diene
nsc315249
NCGC00090822-01
4,5,6,7-tetrahydro-3,6-dimethylcoumarone
3,9-epoxy-p-mentha-3,8-diene
nsc 315249
fema no. 3235
einecs 207-795-5
4,5,6,7-tetrahydro-3,6-dimethylbenzofuran
494-90-6
C09868
menthofuran
4,5,6,7-tetrahydro-3,6-dimethylbenzofuran, >=95%
3,6-dimethyl-4,5,6,7-tetrahydro-1-benzofuran
(r)-4,5,6,7-tetrahydro-3,6-dimethylbenzofuran
CHEBI:50542 ,
CHEMBL1522900
NCGC00090822-02
tox21_200722
cas-494-90-6
dtxsid9025534 ,
NCGC00258276-01
dtxcid005534
SCHEMBL1472618
unii-lk024v9u3c
lk024v9u3c ,
bdbm50418084
FT-0617128
AKOS015906818
(r)-(+)-menthofuran
menthofuran, (+/-)-
3,6-dimethyl-4,5,6,7-tetrahydrobenzofuran
3,6-dimethyl-4,5,6,7-tetrahydro-1-benzofuran #
mfcd00041851
3,9-epoxy-(+)-p-mentha-3,8-diene
4,5,6,7-tetrahydro-3,6-dimethyl-(r)-benzofuran
4,5,6,7-tetrahydro-3,6-dimethyl-benzofuran
FT-0772068
Q6817554
(+/-)-menthofuran
3,6-dimethyl-4,5,6,7-tetrahydrobenzo[b]furan
SB47674
AS-76978

Research Excerpts

Overview

Menthofuran is a hepatotoxin and a major metabolite of pulegone. Pulegone is a monoterpene found in the essential oils of many mint species.

ExcerptReferenceRelevance
"Menthofuran is a hepatotoxin and a major metabolite of pulegone, a monoterpene found in the essential oils of many mint species. "( Tandem mass spectrometric analysis of S- and N-linked glutathione conjugates of pulegone and menthofuran and identification of P450 enzymes mediating their formation.
Lassila, T; Mattila, S; Pelkonen, O; Tolonen, A; Turpeinen, M, 2016
)
2.1
"Menthofuran is a monoterpene present in mint plants that is oxidized by mammalian cytochrome P450 (CYP) to hepatotoxic metabolites. "( Metabolism and toxicity of menthofuran in rat liver slices and in rats.
Khojasteh, SC; Nelson, SD; Oishi, S, 2010
)
2.1
"(+)-Menthofuran is an undesirable monoterpenoid component of peppermint (Mentha x piperita) essential oil that is derived from the alpha,beta-unsaturated ketone (+)-pulegone. "( Demonstration that menthofuran synthase of mint (Mentha) is a cytochrome P450 monooxygenase: cloning, functional expression, and characterization of the responsible gene.
Bertea, CM; Croteau, R; Karp, F; Maffei, M; Schalk, M, 2001
)
1.2

Effects

ExcerptReferenceRelevance
"Menthofuran has been shown to account for a significant percentage of pulegone toxicity through further metabolism to a reactive intermediate, an enonal (2-Z-(2'-keto-4'-methylcyclohexylidene)propanal)."( Metabolism of (R)-(+)-menthofuran in Fischer-344 rats: identification of sulfonic acid metabolites.
Burka, LT; Chen, LJ; Lebetkin, EH, 2003
)
1.35

Toxicity

ExcerptReferenceRelevance
" Simple dose-toxicity studies of a metabolite will help to elucidate its toxic effect, but it is not possible to quantify its role in the toxicity produced by the parent compound unless the disposition of the preformed and endogenously formed metabolite is taken into account."( Contribution of menthofuran to the hepatotoxicity of pulegone: assessment based on matched area under the curve and on matched time course.
Nelson, SD; Slattery, JT; Thomassen, D, 1988
)
0.62
" One patient died, one received N-acetylcysteine, and two ingested minimally toxic amounts of pennyroyal and were not treated with N-acetylcysteine."( Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature.
Anderson, IB; Blanc, PD; Meeker, JE; Mullen, WH; Nelson, SD; Oishi, S, 1996
)
0.29
" Data on human metabolites may provide new insights into the toxic mechanisms and treatment of pennyroyal poisoning, including the potential role of N-acetylcysteine."( Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature.
Anderson, IB; Blanc, PD; Meeker, JE; Mullen, WH; Nelson, SD; Oishi, S, 1996
)
0.29
" Although less toxic than DDVP, all three prototype compounds were toxic to house flies."( Vapor toxicity of three prototype volatile insecticidal compounds to house fly (Diptera: Muscidae).
Chaskopoulou, A; Koehler, PG; Pereira, RM; Scharf, ME, 2009
)
0.35

Dosage Studied

Menthofuran is a GSH conjugate of the enonal that has been partially characterized in bile of rats dosed with pulegone. To test this hypothesis, male and female rats were dosed orally with 14C-labeled Pulegone or menthofuran.

ExcerptRelevanceReference
" 2-(Glutathion-S-yl)menthofuran, a GSH conjugate of the enonal that has been partially characterized in bile of rats dosed with pulegone, is at most a minor biliary metabolite of menthofuran in rats."( Metabolism of (R)-(+)-menthofuran in Fischer-344 rats: identification of sulfonic acid metabolites.
Burka, LT; Chen, LJ; Lebetkin, EH, 2003
)
0.96
" To test this hypothesis, male and female rats were dosed orally with 14C-labeled pulegone (80 mg/kg, 120 microCi/kg) or menthofuran (60 mg/kg, 120 microCi/kg) or menthones (80 mg/kg, 120 microCi/kg) in corn oil, and the kidney cytosol was prepared 24 h after dosing."( 14C-labeled pulegone and metabolites binding to alpha2u-globulin in kidneys of male F-344 rats.
Borghoff, SJ; Burka, LT; Ferguson, LJ; Lebetkin, EH; Lih, FB; Parkinson, HD; Tomer, KB, 2007
)
0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
nematicideA substance used to destroy pests of the phylum Nematoda (roundworms).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
1-benzofuransA member of the class of benzofurans consisting of a 1-benzofuran skeleton and its substituted derivatives thereof.
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
pregnane X receptorRattus norvegicus (Norway rat)Potency56.23410.025127.9203501.1870AID651751
AR proteinHomo sapiens (human)Potency31.62280.000221.22318,912.5098AID588515
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency17.78280.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency50.86920.001022.650876.6163AID1224838; AID1224839; AID1224893
pregnane X nuclear receptorHomo sapiens (human)Potency24.70700.005428.02631,258.9301AID1346982; AID720659
aryl hydrocarbon receptorHomo sapiens (human)Potency20.25600.000723.06741,258.9301AID743085; AID743122
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency74.97800.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2A6Homo sapiens (human)Ki0.84000.00561.52717.5000AID589222
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID589222Mechanism based inhibition of human cytochrome P450 2A6 measured by coumarin 7-hxdroxylation using purified P4502005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID589182Mechanism based inhibition of human cytochrome P450 2A6, partition ratio2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID589227Mechanism based inhibition of human cytochrome P450 2A6 measured by coumarin 7-hydroxylation using human liver microsomes2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (14.89)18.7374
1990's11 (23.40)18.2507
2000's13 (27.66)29.6817
2010's15 (31.91)24.3611
2020's1 (2.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.73 (24.57)
Research Supply Index3.93 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index55.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (6.00%)6.00%
Case Studies2 (4.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]